Skip to content
Study details
Enrolling now

CTSN Embolic Protection Trial

Icahn School of Medicine at Mount Sinai
NCT IDNCT06027788ClinicalTrials.gov data as of Apr 2026
Target enrollment

842

Study length

about 3.5 years

Ages

60+

Locations

24 sites in AR, CA, GA +14

What this study is about

Researchers are testing a new device called CardioGard to protect against blood clots in patients undergoing valve surgery. The trial will compare the CardioGard device to a standard cannula, which is a tube used during surgery. It will last for 12 months after the surgery.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Use CardioGard Embolic Protection Cannula
  • 2.Use Standard Aortic Cannula

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: All-cause mortality, Length of Index Hospitalization, Montreal Cognitive Assessment (MoCA) Score

Devices

therapeutic

Body systems

Neurology, Renal, Cardiology / Heart